Soluble Fc Gamma Receptor Stability Assay via Aggregated IgG Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a reliable in vitro method to determine the stability of compositions comprising soluble human Fc gamma receptors, particularly for pharmaceutical compositions like SM101, which may degrade during storage, necessitating reproducible tests to assess residual activity.
Innovation Solution
An in vitro method involving contacting a surface with human Fc gamma receptors with aggregated human IgG, measuring the bound IgG, and comparing it to a reference value to determine the stability of the composition, utilizing a kit that includes a surface and aggregated human IgG, with the method applicable to pharmaceutical compositions containing soluble human Fc gamma receptor IIA, IIB, IIIA, and/or IIIB.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If soluble human Fc gamma receptors are stored in pharmaceutical compositions, then they maintain therapeutic availability, but they may degrade during storage losing stability
Solution Approach 1:
The patent performs stability assessment before the composition is fully stored and deployed. By conducting in vitro binding assays with aggregated human IgG beforehand, the method predicts long-term stability and allows formulation adjustments to be made proactively, preventing degradation before it occurs during extended storage.
Solution Approach 2:
The patent establishes a feedback mechanism where stability test results from in vitro assays are used to evaluate and adjust the pharmaceutical composition. The binding capacity measurements provide feedback on receptor stability, allowing iterative optimization of formulation conditions to maintain stability throughout the storage duration.
2Stability of the object's composition
If in vitro methods are developed to test stability, then storage conditions can be optimized, but the complexity of testing increases
Solution Approach 1:
The patent creates an in vitro copy of the in vivo binding environment by using aggregated human IgG to mimic physiological conditions. This simplified model system replicates the essential binding interactions without requiring complex in vivo models, allowing stability assessment through manageable laboratory assays while maintaining biological relevance.
Solution Approach 2:
The patent utilizes measurable parameters such as binding capacity and affinity constants (KD values) to quantify stability. By changing and monitoring these physical-chemical parameters during storage and testing, the method transforms a complex stability assessment into quantifiable measurements that can be systematically evaluated and compared.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the determination of the stability and binding capacity of soluble human Fc gamma receptors, enabling the assessment of shelf stability and residual activity, ensuring the quality and potency of pharmaceutical compositions like SM101, and can be used for quality control and dosage determination.
Implementation Method 1
contacting a surface comprising human Fc gamma receptor IIA, IIB, IIIA and/or IIIB with a set amount of aggregated human IgG; determining the amount of aggregated human IgG which is bound to said surface
Data Source
AI summary
The present invention relates in essence to an in vitro method for determining the stability, such as the shelf stability; stability over time; shelf life of a composition which comprises or essentially consists of soluble human Fc gamma receptor IIA, MB, IIIA and/or 1 MB, said method comprising the steps of contacting a surface comprising human Fc gamma receptor IIA, MB, IIIA and/or 1 MB with a set amount of aggregated human IgG; contacting said surface comprising human Fc gamma receptor IIA, MB, IIIA and/or 1 MB with a set amount of said composition of soluble human Fc gamma receptor IIA, MB, IIIA and/or 1 MB; determining the amount of aggregated human IgG which is bound to said surface comprising said human Fc gamma receptor IIA, MB, IIIA and/or 1 MB, and comparing the amount of aggregated human IgG which is bound to said surface as determined in step (c) with a reference value and (thereby) determining the stability [shelf stability; stability over time; shelf life] of said composition which comprises or essentially consists of soluble human Fc gamma receptor IIA, MB, IIIA and/or 1 MB. The present invention also relates to aggregated human IgG obtainable by a method as defined herein, as well as to the use of the mentioned aggregated human IgG in the methods of the invention.